Vilon is one of the shortest peptides in science that still does something biologically interesting. It is a two-amino-acid molecule, L-lysyl-L-glutamic acid (Lys-Glu, abbreviated KE), developed by Professor Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology as part of a long Russian research program into tissue-specific "peptide bioregulators."[3][4] This guide explains what Vilon actually is, the immune and anti-aging research behind it, how it compares to related bioregulators like epitalon and thymalin, the dosing figures reported in the literature, and the honest safety and regulatory picture in 2026.
🔑 Key Takeaways
- Vilon is the synthetic dipeptide L-Lys-L-Glu (KE), one of the shortest peptides with documented biological activity, developed by Khavinson's group as a thymus-derived immune and aging bioregulator.[3][4]
- Its best-known mechanism is gene regulation: in lymphocytes, Lys-Glu stimulated interleukin-2 (IL-2) gene expression in a concentration- and time-dependent way, and the broader bioregulator theory holds that these short peptides influence tissue-specific gene activity.[2][3]
- In a long-term mouse study, Vilon inhibited the growth of spontaneous tumors and increased lifespan, reduced spontaneous lung adenomas, and raised physical activity without affecting body weight or food intake.[1]
- Across the Khavinson bioregulator class, rodent studies have reported roughly 20 to 40 percent extensions of lifespan, with Vilon studied alongside epitalon and thymalin.[3]
- Vilon is not FDA-approved in the United States. Products are sold for laboratory research only, and the human evidence is largely older or small Russian clinical work, not modern placebo-controlled trials.[5]
What Is Vilon?
Vilon is a synthetic dipeptide built from just two amino acids, lysine and glutamic acid, giving the sequence L-Lys-L-Glu (commonly written KE). At two residues it sits at the extreme short end of the peptide spectrum, which is exactly the point: Khavinson's group set out to find the smallest peptide fragments that could still carry a biological signal.[3] Vilon was modeled on, and is chemically related to, the active short peptides found in thymalin, the calf-thymus polypeptide extract studied for decades in Russia. Thymalin is in fact a mixture that contains KE (vilon) alongside other active fragments, so Vilon can be thought of as one purified, defined piece of that older thymic preparation.[4]
It belongs to a wider family of "peptide bioregulators" that also includes epitalon, the pineal tetrapeptide, and pinealon. If you want the full theory behind how these short organ-specific peptides are proposed to work, our complete guide to bioregulator peptides and our bioregulator peptides for aging guide cover the regulatory-peptide concept in detail and place Vilon in context next to thymalin, epitalon, and pinealon.
How Vilon Is Thought to Work
The headline idea behind the Khavinson peptides is gene regulation. Rather than acting as a hormone or a blunt stimulant, these short peptides are proposed to influence which genes a given tissue switches on, effectively nudging cells back toward a younger pattern of activity.[3] Vilon gave one of the cleaner pieces of evidence for this: in cultured lymphocytes, the Lys-Glu peptide stimulated expression of the interleukin-2 (IL-2) gene, and the effect depended on both peptide concentration and how long the cells were exposed. The authors proposed that Vilon may be the shortest regulatory fragment capable of helping activate IL-2 gene transcription in immune cells.[2]
That single, well-defined gene-expression result is the load-bearing mechanistic finding for Vilon. The broader claims you will see online, that these peptides bind DNA directly and reprogram aging cells across many genes, come from the wider Khavinson bioregulator theory and reviews rather than from large independent replications, so they are best treated as a working hypothesis rather than settled fact.[3]
Vilon Benefits: What the Research Actually Shows
Almost all of the meaningful Vilon data is preclinical (cell and animal studies) plus older Russian clinical observation. Here is what the strongest sources actually report, separated from the marketing.
Immune Regulation
Vilon's thymic lineage and its IL-2 result point in the same direction: immune modulation. IL-2 is a central signal for T-cell growth and coordination, so a peptide that nudges IL-2 gene expression upward in lymphocytes is, in principle, supporting the orchestration of the immune response rather than simply revving it.[2] In the older bioregulator literature, the thymalin family (which includes KE) was used for "immune correction" and as a geroprotector in elderly cohorts, where age-related thymic decline blunts immune function.[4] If you are exploring immune-focused peptides more broadly, see our roundups of the best peptides for immune support and the best peptides for the immune system in 2026, plus the more clinically developed thymosin alpha-1 peptide.
Anti-Aging and Longevity
The most striking Vilon data is the mouse longevity work. In a long-term study, the Lys-Glu dipeptide inhibited the growth of spontaneous tumors and increased the lifespan of mice. It also reduced the incidence of spontaneous lung adenomas and increased the animals' physical activity, while it did not significantly change body weight, food consumption, free-radical processes, or estrus function.[1] That profile, longer life and fewer tumors without obvious metabolic disruption, is what put Vilon on the longevity-research map.
Vilon does not stand alone here. Reviews of the whole Khavinson bioregulator class report lifespan extensions of roughly 20 to 40 percent in rodents across compounds, with Vilon studied alongside epitalon and other short peptides.[3] For the broader anti-aging peptide landscape and how these geroprotectors compare, our guide to the best anti-aging peptides for 2026 is a useful companion read.
What the mouse data does and does not mean
Increasing lifespan and reducing tumors in mice is a genuinely interesting signal, but it is not the same as proven anti-aging in humans. Rodent-to-human translation is not linear, the dosing was an animal protocol, and there are no large modern human trials of Vilon. Treat the longevity findings as promising early research, not as a clinical result you can extrapolate to yourself.[1][5]
Other Reported Effects
Because Vilon is positioned as an organ-tuning bioregulator rather than a single-target drug, vendor and review material often lists wide-ranging effects (skin, gut, vascular, cognitive). The honest summary is that the rigorously documented effects are the immune/gene-expression result and the mouse lifespan and anti-tumor data above; most other claims are extrapolated from the general bioregulator theory and have far less direct evidence behind them.[2][3]
Vilon vs Other Bioregulator Peptides
Because the Khavinson peptides share a naming style and a theory, they are easy to confuse. Here is a side-by-side reference to keep them straight.
| Peptide | Sequence / size | Associated tissue | Primary research focus |
|---|---|---|---|
| Vilon | Lys-Glu (KE), dipeptide (2 aa) | Thymus / immune | IL-2 gene expression, mouse lifespan and anti-tumor effects[1][2] |
| Epitalon | Ala-Glu-Asp-Gly (AEDG), tetrapeptide (4 aa) | Pineal gland | Melatonin/circadian rhythm, telomerase and aging research[3] |
| Thymagen (Thymogen) | Glu-Trp (EW), dipeptide (2 aa) | Thymus / immune | T-cell differentiation, phagocytosis, anti-aging in rats[4] |
| Thymalin | Polypeptide complex (mixture) | Thymus extract | Parent extract that contains KE (vilon) and EW; immune correction in the elderly[4] |
The quick way to remember it: Vilon (KE) and Thymagen (EW) are both tiny thymic dipeptides pulled out of thymalin, while epitalon and pinealon are pineal/brain peptides. All four are studied under the same geroprotection umbrella, which is why our bioregulator peptides for aging guide treats them together.
Reported Vilon Dosage and Protocols
There is no FDA-approved Vilon dose in the United States. The figures below summarize what appears in historical Russian clinical practice and in research-product references. They are presented for completeness and context, not as a protocol to follow.
| Use context | Route in the literature | Reported research range | Typical reported course |
|---|---|---|---|
| Historical Russian clinical use | Intramuscular injection | Roughly 5 to 10 mcg per administration | Once daily for about 10 days, sometimes repeated cyclically |
| Modern research-product references | Subcutaneous (reconstituted) | Vendor-reported microgram ranges (often tens of mcg) | Short cycles of 10 to 20 days |
| Animal longevity study | Subcutaneous | Microgram-level dosing per animal | Intermittent dosing across the lifespan[1] |
Anyone handling lyophilized research peptides also has to get the reconstitution and unit math right, which is the same logic regardless of compound. Our TB-500 dosage guide walks through that reconstitution and dosing arithmetic in detail, and the how long to take thymosin alpha-1 article covers how cycle length is reasoned about for thymic peptides.
Vilon Side Effects and Safety
In the older clinical literature, the thymalin-family peptides (including KE) were generally described as well tolerated, with their main documented roles being immune correction during infection and geroprotection in elderly subjects.[4] No distinctive, consistent toxicity has been reported for Vilon at the low microgram doses used, and the mouse study specifically noted no significant effect on body weight, food intake, or free-radical processes.[1]
The honest caveat is the size and age of the evidence. There are no large, modern, placebo-controlled human safety trials of isolated Vilon. Most contemporary products are explicitly sold "for laboratory research use only, not for human consumption," and the long-term effects of self-administration are simply not characterized.[5] As with any immune-modulating compound, people who are pregnant, breastfeeding, immunosuppressed, or taking immune-affecting medication should be especially cautious, because shifting immune signaling can interact with existing conditions and treatments.
Who should be most cautious
- Anyone pregnant or breastfeeding (no adequate safety data).
- People on immunosuppressants or active immune therapy (immune modulation can interfere).
- Anyone expecting a proven anti-aging or anti-cancer result. The strong data are in mice, not humans.[1]
Where to Buy Vilon and Is It Available?
Vilon is a niche research peptide, so it is not stocked as widely as mainstream compounds, and it is sold strictly for research rather than as a supplement or medicine.[5] If you are sourcing research peptides, the things that matter most are US-based manufacturing, published purity testing, and clear lot information, since quality varies widely across the gray market. For vetted vendor criteria we apply the same standards we use in our where to buy thymosin alpha-1 guide. New to the category entirely? Start with what are peptides for the fundamentals before buying anything.
Because regulatory status is research-only and product quality is inconsistent, treat any Vilon purchase as experimental and verify the vendor's testing claims before ordering.
Frequently Asked Questions
Bottom Line
Vilon is a real, well-characterized short peptide with a genuinely interesting research story: a two-amino-acid bioregulator that nudges IL-2 gene expression in immune cells and, in mice, extended lifespan while suppressing spontaneous tumors.[1][2] It sits squarely in the Khavinson bioregulator family alongside epitalon and thymalin, where the class as a whole has shown 20 to 40 percent lifespan extension in rodents.[3][4] What Vilon is not is a finished, human-proven therapy. The strongest evidence is preclinical, the human data are old and limited, and the US regulatory status is research-only.[5] If you are drawn to the longevity and immune angle, read it as promising early science, weigh sourcing quality carefully, and involve a qualified clinician before considering any peptide.
References
- Khavinson VKh, Anisimov VN. A synthetic dipeptide vilon (L-Lys-L-Glu) inhibits growth of spontaneous tumors and increases life span of mice. Dokl Biol Sci. 2000;372:261-263 (PMID 10944717).
- Khavinson VKh, et al. Effect of peptide Lys-Glu on interleukin-2 gene expression in lymphocytes. Bull Exp Biol Med. 2000 (PMID 11177276).
- Anisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139-149.
- Khavinson VK, et al. The Use of Thymalin for Immunocorrection (thymalin contains KE/vilon and EW) and geroprotective clinical observations. Biology Bulletin Reviews (PMC8365293), 2021.
- FDA. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act.